Agios Pharmaceuticals, Inc. (LON: 0HB0)
London
· Delayed Price · Currency is GBP · Price in USD
33.39
-0.52 (-1.53%)
Jan 23, 2025, 2:30 PM BST
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $8.96M USD in the quarter ending September 30, 2024, with 21.15% growth. This brings the company's revenue in the last twelve months to $32.87M, up 36.79% year-over-year. In the year 2023, Agios Pharmaceuticals had annual revenue of $26.82M with 88.36% growth.
Revenue (ttm)
$32.87M
Revenue Growth
+36.79%
P/S Ratio
n/a
Revenue / Employee
$85.16K
Employees
386
Market Cap
1.58B GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Agios Pharmaceuticals News
- 9 days ago - Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision - Seeking Alpha
- 10 days ago - Agios Pharmaceuticals Inc (AGIO) Announces Key Milestones and Strategic Plans for 2025 - GuruFocus
- 15 days ago - Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer - Business Wire
- 20 days ago - Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - GlobeNewsWire
- 27 days ago - The best U.S. value stocks by Quant: AGIO, DLX, PPC - Seeking Alpha
- 5 weeks ago - European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - GlobeNewsWire
- 6 weeks ago - Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug - Investor's Business Daily
- 6 weeks ago - Agios reports results from late-stage study of its thalassemia treatment - Seeking Alpha